Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “GEP Neuroendocrine Tumor”

120 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 120 results

Not applicableLooking for participantsNCT04282083
What this trial is testing

Protocol ITANET - Registry

Who this might be right for
Gastro-entero Pancreatic Neuroendocrine Tumors
Italian Association Neuroendocrine Tumors 3,600
Not applicableLooking for participantsNCT06981455
What this trial is testing

Life Following Excision of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine (NE) TumorsNeuroendocrine Tumor GEP Grade 1-3
Sunnybrook Health Sciences Centre 246
Testing effectiveness (Phase 2)Active Not RecruitingNCT01841736
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Who this might be right for
Foregut Neuroendocrine TumorHindgut Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1+5 more
National Cancer Institute (NCI) 171
Not applicableLooking for participantsNCT06735560
What this trial is testing

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN

Who this might be right for
Hepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)Neuroendocrine Tumors
Nantes University Hospital 60
Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14
Testing effectiveness (Phase 2)Looking for participantsNCT06427798
What this trial is testing

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Who this might be right for
Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytoma+1 more
National Cancer Institute (NCI) 66
Testing effectiveness (Phase 2)Ended earlyNCT02736448
What this trial is testing

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Testing effectiveness (Phase 2)UnknownNCT03457844
What this trial is testing

Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor G3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT01010126
What this trial is testing

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Who this might be right for
Adult Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaEndometrial Serous Adenocarcinoma+42 more
National Cancer Institute (NCI) 252
Early research (Phase 1)Not Yet RecruitingNCT07488923
What this trial is testing

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Who this might be right for
Small Cell Lung Cancer (SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)+1 more
Moonlight Bio, Inc 110
Not applicableUnknownNCT02838862
What this trial is testing

Identification of Biomarker Profiles GEP-NEN Patients

Who this might be right for
Neuroendocrine Tumors
University Hospital Schleswig-Holstein 470
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Large-scale testing (Phase 3)Ended earlyNCT01755182
What this trial is testing

Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
National Cancer Institute, Naples 1
Very early researchActive Not RecruitingNCT04993261
What this trial is testing

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Who this might be right for
Carcinoid SyndromeCarcinoid TumorDigestive System Neuroendocrine Tumor G1+1 more
M.D. Anderson Cancer Center 71
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600233
What this trial is testing

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic Neuroendocrine TumorGastro-enteropancreatic Neuroendocrine Tumor+2 more
TaiRx, Inc. 34
Testing effectiveness (Phase 2)Ended earlyNCT05987176
What this trial is testing

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Who this might be right for
Neuroendocrine Tumor G1 (NET G1)/CarcinoidNeuroendocrine Tumor Grade 2Neuroendocrine Tumors+3 more
Imperial College London 1
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Not applicableStudy completedNCT03017690
What this trial is testing

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 22
Not applicableStudy completedNCT03288402
What this trial is testing

Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients

Who this might be right for
Neuroendocrine Tumors
University Hospitals Coventry and Warwickshire NHS Trust 346
Load More Results